CLINICAL TRIAL SUMMARY

MDACC Study No:2009-0163 (clinicaltrials.gov NCT No: NCT00904722)
Title:Phase II Safety and Efficacy Study of the Monoclonal Antibody CT-011 in combination with Rituximab in Patients with Relapsed Follicular Lymphoma
Principal Investigator:Sattva S. Neelapu
Treatment Agent:CT-011 Monoclonal Antibody; Rituximab
Study Status:Closed
Study Description:The goal of this clinical research study is to learn if the combination of the
immunotherapy drugs, CT-011 and rituximab, can help control follicular
lymphoma. The safety of this drug combination will also be studied.

Hide details for General InformationGeneral Information

Disease Group:Lymphoma
Phase of Study:Phase II
Treatment Agents:CT-011 Monoclonal Antibody
Rituximab
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:N/A
Supported By:Cure Tech Ltd
Return Visit:Pre-treatment, days 1, 2, 7, 14, 17, 24, 29, 31, 38, 43, 57, 85, and weeks 16,
20, 24, 28, 32, 36, 40, 44, 52, 64, 76, 88, 100, 112, and 124.
Home Care:N/A


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Sattva S. Neelapu
Dept:Lymphoma/Myeloma
For Clinical Trial Enrollment:713-792-2860
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults